New hope for tough cancers: trial tests Next-Gen drug combo
NCT ID NCT05318573
Summary
This study is testing a new drug called FF-10832, both by itself and combined with an existing immunotherapy (pembrolizumab), for people with advanced lung or bladder cancer. The main goals are to find a safe dose and see if the treatment can help control the cancer. It is for patients whose cancer has continued to grow despite previous treatment with similar immunotherapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atlantic Health System / Morristown Medical Center
Morristown, New Jersey, 07960, United States
-
Avera Cancer Institute
Sioux Falls, South Dakota, 57105, United States
-
Cancer and Blood Speciality Clinic
Long Beach, California, 90806, United States
-
Comprehensive Cancer Centers of Nevada - Southern Hills
Las Vegas, Nevada, 89148, United States
-
Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion)
Detroit, Michigan, 48202, United States
-
Hospital of the Univ of Pennsylvania Perlman Center
Philadelphia, Pennsylvania, 19104, United States
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
-
NYU Langone Health
New York, New York, 10016, United States
-
Nebraska Cancer Specialists - Legacy
Omaha, Nebraska, 68130, United States
-
Providence Cancer Institute Franz Clinic
Portland, Oregon, 97213, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
Sharp Memorial Hospital (Oncology Clinical Research)
San Diego, California, 92123, United States
-
Sibley Memorial Hospital
Washington D.C., District of Columbia, 20016, United States
-
TriHealth Cancer Institute; Good Samaritan Hospital
Cincinnati, Ohio, 45220, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
University of Kansas Cancer Center - Westwood
Westwood, Kansas, 66205, United States
-
University of Kentucky Medical Center
Lexington, Kentucky, 40536, United States
-
University of Louisville Brown Cancer Center
Louisville, Kentucky, 40202, United States
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75235, United States
-
University of Wisconsin Clinical Science Center
Madison, Wisconsin, 53792, United States
-
Virginia Cancer Specialists, PC
Fairfax, Virginia, 22031, United States
-
Washington University School of Medicine, Center for Adv Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.